Merck & Co., Inc. (MRK)
150.72
-1.83
(-1.20%)
USD |
NYSE |
Aug 24, 16:00
151.39
+0.67
(+0.44%)
After-Hours: 20:00
Merck Enterprise Value : 423.37B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 423.37B |
| August 20, 2026 | 414.58B |
| August 19, 2026 | 422.50B |
| August 18, 2026 | 380.46B |
| August 17, 2026 | 382.44B |
| August 14, 2026 | 382.12B |
| August 13, 2026 | 381.40B |
| August 12, 2026 | 374.91B |
| August 11, 2026 | 368.74B |
| August 10, 2026 | 369.97B |
| August 07, 2026 | 364.19B |
| August 06, 2026 | 363.67B |
| August 05, 2026 | 363.58B |
| August 04, 2026 | 362.76B |
| August 03, 2026 | 362.19B |
| July 31, 2026 | 368.19B |
| July 30, 2026 | 367.18B |
| July 29, 2026 | 368.59B |
| July 28, 2026 | 372.19B |
| July 27, 2026 | 369.57B |
| July 24, 2026 | 370.34B |
| July 23, 2026 | 368.88B |
| July 22, 2026 | 361.45B |
| July 21, 2026 | 358.47B |
| July 20, 2026 | 353.87B |
| Date | Value |
|---|---|
| July 17, 2026 | 361.53B |
| July 16, 2026 | 361.85B |
| July 15, 2026 | 351.92B |
| July 14, 2026 | 344.94B |
| July 13, 2026 | 352.96B |
| July 10, 2026 | 351.75B |
| July 09, 2026 | 355.53B |
| July 08, 2026 | 357.80B |
| July 07, 2026 | 364.88B |
| July 06, 2026 | 359.75B |
| July 02, 2026 | 366.61B |
| July 01, 2026 | 356.27B |
| June 30, 2026 | 364.00B |
| June 29, 2026 | 362.93B |
| June 26, 2026 | 361.15B |
| June 25, 2026 | 353.22B |
| June 24, 2026 | 341.24B |
| June 23, 2026 | 338.77B |
| June 22, 2026 | 328.60B |
| June 18, 2026 | 324.62B |
| June 17, 2026 | 328.50B |
| June 16, 2026 | 327.83B |
| June 15, 2026 | 327.16B |
| June 12, 2026 | 337.41B |
| June 11, 2026 | 341.64B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 679.08B |
| Eli Lilly & Co. | 1.228T |
| Pfizer Inc. | 211.77B |
| Bristol Myers Squibb Co. | 170.89B |
| Abbott Laboratories | 229.49B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.337B |
| Revenue (Quarterly) | 16.58B |
| Total Expenses (Quarterly) | 17.92B |
| EPS Diluted (Quarterly) | -0.5405 |
| Gross Profit Margin (Quarterly) | 71.51% |
| Profit Margin (Quarterly) | -8.06% |
| Earnings Yield | 0.83% |
| Operating Earnings Yield | 3.33% |
| Normalized Earnings Yield | 2.007 |